MAYO CLINIC LABORATORIES

NEW TEST

Notification Date: January 30, 2024
Effective Date: January 30, 2024

Preeclampsia sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase 1/ Placental Growth Factor) Ratio, Serum

Test ID: PERA

Useful for:

To aid in risk assessment of patients with clinical signs and symptoms consistent with development of preeclampsia with severe features.

The test is indicated for use in pregnant women, with singleton pregnancies (gestational age 23 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension), within 2 weeks of presentation.

Methods:

Immunofluorescent Assay (IFA)

Reference Values:

<40

Specimen Requirements:

Preferred Container/Tube:	Serum Gel
Acceptable Container/Tube:	Red Top
Submission Container/Tube:	Plastic vial
Specimen Volume:	0.5 mL
Collection Instructions:	Centrifuge and aliquot serum into a plastic vial
Minimum Volume:	0.3 mL

Specimen Stability Information:

Specimen Type	Temperature	Time
Serum	Frozen (preferred)	6 months
	Refrigerated	24 hours

Cautions:

B·R·A·H·M·S PlGF plus KRYPTOR must be run in conjunction with B·R·A·H·M·S sFlt-1 KRYPTOR and the same patient sample must be used to run both assays. Use of another manufacturer's assays may result in significantly different results.

PIGF sFlt-1 The sFlt-1/PlGF ratio should not be used for a woman with a multiple pregnancy because the safety and effectiveness of the assay has not been established in pregnant women with a multiple pregnancy (i.e., pregnancy with more than one fetus).

The sFlt-1/PlGF ratio should not be used for a woman receiving intravenous heparin for 24 hours prior to testing because the safety and effectiveness of the assay has not been established in pregnant women who received intravenous heparin within 24 hours of testing.

The sFlt-1/PlGF ratio should not be used for a woman receiving exogenous PlGF-2 or PlGF-3 for therapeutic use at concentration higher than 100 pg/mL because the safety and effectiveness of the assay has not been established in pregnant women who received exogenous PlGF-2 or PlGF-3 for therapeutic use at concentrations higher than 100 pg/mL. However, in samples with equal concentrations of PIGF (PIGF 1), and PIGF 2 the measurement of PIGF 1 was relatively unaffected.

The results of the test are not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.

The results of the test are not a stand-alone test for monitoring of hypertensive disorders of pregnancy.

The results of the test are not intended to inform the healthcare provider whether or not to change treatment, including medication or hospitalization.

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies (HAMA) or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results and the laboratory should be alerted if the result does not correlate with the clinical presentation.
header

CPT Code:

81599

Day(s) Performed: Monday through Saturday **Report Available:** 1 to 3 days

Questions

Contact Bethany Feind, Laboratory Resource Coordinator at 800-533-1710.